Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • breezerwave breezerwave Dec 8, 2012 7:24 AM Flag

    EXEL:Some great news and we take off

    Isn't this great news?

    One can google the article:

    Cabozantinib Prolongs PFS in Advanced Prostate Cancer

    A new study is reporting "unprecedented" results in the treatment of castration-resistant prostate cancer (CRPC) with the new drug cabozantinib ( Cometriq, Exelixis).

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "A new study is reporting "unprecedented" results..." It is a recent article, but not a new study. This is the CRPC cohort from the RDT originally reported on in Feb 2011. There will be updates and phase 2 results fairly often, but the market is really only impressed by the results of randomized controlled trials. In that category, next up is the EXAM survival analysis followed by Comet 2, both in the 12-18 month time frame.

 
EXEL
11.15+0.11(+1.00%)Aug 31 4:00 PMEDT